Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at the NLSDays 2017. We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and our ongoing development of a therapeutic antibody [...]
We will present our recent advancements in the development of a biological drug for treatment of chronic inflammatory diseases. Pre-clinical results based on well established models have shown the importance of our novel target molecule, the bile-salt stimulated lipase (BSSL). The development of a humanised antibody is in progress and Lipum is actively seeking partners [...]
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén or Chairman Ulf Björklund at BIO-Europe Spring 2017 in Barcelona. We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and our ongoing development [...]